TL;DR
This study reveals a novel mechanism by which STAG2, a key component of the cohesin complex, regulates gene expression in melanoma. Loss of STAG2 leads to changes in 3D genome organization, specifically the expansion of TADs and altered enhancer-promoter loops, which in turn activates the IRF9 gene. This activation triggers interferon signaling and increases PD-L1 expression, potentially contributing to immune evasion in STAG2-mutant cancers.
What Problem Does This Paper Address?
The cohesin complex is crucial for organizing the 3D genome, forming DNA loops that regulate gene expression. While STAG2, a subunit of cohesin, is frequently mutated in cancers, its specific role in 3D genome organization and its impact on gene expression, particularly in melanoma, remains poorly understood. Previous research has shown STAG2 inactivation can lead to resistance to BRAF inhibitors in melanoma, but the underlying mechanisms, especially concerning genome architecture, were unclear. This paper aims to elucidate how STAG2 loss affects 3D genome organization, specifically long-range enhancer-promoter interactions, and how these changes influence gene expression and potentially contribute to cancer progression and immune evasion.
Methods
The researchers employed a multi-omics approach to investigate the role of STAG2. Key techniques included:
- ChIP-seq (Chromatin Immunoprecipitation Sequencing): Used to map the binding sites of STAG2, STAG1, SMC1A, and CTCF in melanoma cells, both with and without STAG2 knockdown. This allowed them to identify changes in protein binding upon STAG2 loss.
- Hi-C: A genome-wide technique to capture the 3D organization of the genome by crosslinking DNA and sequencing interacting fragments. This was used to assess changes in topologically associating domains (TADs) and contact probabilities.
- H3K27ac HiChIP: A specialized Hi-C technique that enriches for active enhancers and promoters marked by H3K27ac. This allowed for the detailed mapping of enhancer-promoter interactions and how they are affected by STAG2 loss.
- RNA-seq (RNA Sequencing): Used to analyze global gene expression changes upon STAG2 knockdown, identifying differentially expressed genes and enriched pathways.
- CRISPR/Cas9 gene editing: Employed to specifically delete STAG2 binding sites or repress enhancer activity to confirm the functional relevance of identified genomic elements.
- Western Blotting and qPCR: Standard molecular biology techniques used to validate changes in mRNA and protein levels of key genes like IRF9 and PD-L1.
- Flow Cytometry: Used to measure the surface expression of PD-L1 on cancer cells.
- Bioinformatics analysis: Integrated data from these different techniques to identify direct STAG2 targets, analyze genomic patterns, and perform statistical correlations.
A notable aspect of their approach was the integration of these diverse datasets to build a comprehensive picture of how STAG2 influences genome organization and gene regulation.
Datasets
The study utilized data from:
- M14 melanoma cell line: This was the primary cell line used for experimental manipulations (STAG2 knockdown, CRISPR editing) and molecular profiling (ChIP-seq, Hi-C, RNA-seq, HiChIP).
- The Cancer Genome Atlas (TCGA) SKCM dataset: This dataset provided bulk RNA-seq data from 473 cutaneous melanoma tumors, used for correlating STAG2, IRF9, and PD-L1 mRNA expression levels in human samples.
- A cohort of metastatic melanoma patients treated with PD-1 immune checkpoint blockade: This dataset was used to assess the association between STAG2 expression and response to immunotherapy.
Key Insights and Ideas
- STAG2 to STAG1 Switch: Loss of STAG2 in melanoma cells doesn't just remove its function; it often leads to its paralog, STAG1, taking its place at specific genomic sites. This "switch" is not a simple one-to-one replacement and appears to have distinct functional consequences.
- TAD Expansion: STAG2 inactivation leads to an expansion of topologically associating domains (TADs), particularly at their boundaries. This suggests STAG2 plays a role in maintaining the integrity of these genomic compartments.
- Enhancer Loop Reprogramming: The STAG2 to STAG1 switch is associated with enhanced formation of H3K27ac-marked enhancer-promoter loops. This reprogramming of interactions is a key mechanism by which STAG2 loss alters gene expression.
- IRF9 as a Direct Target: Interferon Regulatory Factor 9 (IRF9) is identified as a direct target of STAG2. STAG2 normally represses IRF9 expression, and its loss leads to IRF9 activation.
- Interferon Signaling and PD-L1 Upregulation: Activated IRF9, in turn, boosts type I interferon signaling, which is known to increase the expression of PD-L1. PD-L1 is a critical immune checkpoint protein that cancer cells use to evade immune surveillance.
- Potential for Immune Evasion: The findings suggest that STAG2-mutant melanomas might exploit this pathway to enhance their immune evasion potential by upregulating PD-L1.
Key Results
- STAG2 KD leads to TAD expansion: The average size of TADs significantly increased upon STAG2 knockdown (p = 3.488e-13).
- STAG2 to STAG1 switch at TAD boundaries: Approximately 41% of STAG2 binding sites lost upon knockdown showed increased STAG1 binding, suggesting a compensatory switch. This switch was particularly prominent at TAD boundaries.
- Enhanced H3K27ac loops: STAG2 knockdown resulted in a significant number of enhanced H3K27ac-associated loops (9115 enhanced vs. 11327 impaired).
- Gain of H3K27ac at switch sites: H3K27ac signal significantly increased at STAG2 to STAG1 switch sites upon STAG2 KD (p < 2.2e-16).
- IRF9 activation upon STAG2 KD: Knockdown of STAG2 led to increased mRNA and protein levels of IRF9 in multiple melanoma cell lines.
- PD-L1 upregulation: STAG2 knockdown also increased PD-L1 mRNA, protein, and surface expression. CRISPR knockout of IRF9 reversed this PD-L1 induction.
- Clinical correlations: In TCGA SKCM data, STAG2 expression was negatively correlated with IRF9 (Spearman r = -0.21) and positively correlated with PD-L1 (Spearman r = 0.5).
- Therapeutic implications: Lower STAG2 mRNA expression was associated with increased response to anti-PD-1 therapy (p = 0.048), and higher STAG2 expression correlated with worse progression-free survival.
Limitations and Future Work
- Technical limitations of Hi-C: The authors acknowledge that the scope of their Hi-C analysis might be limited, and they suggest that a mix of technical and biological variations could contribute to observed TAD organization changes.
- Mechanism of TAD expansion: While they observed that the STAG2 to STAG1 switch at TAD boundaries is associated with TAD expansion, the precise molecular mechanism underlying this is still unknown. They note STAG2's higher affinity for WAPL, a loop extrusion regulator, as a potential avenue for future investigation.
- Context-dependent role of interferon signaling: The authors acknowledge that type I interferon signaling can have context-dependent effects in tumor biology, being either pro- or anti-tumor. Further research is needed to fully understand the implications of STAG2's role in regulating this pathway in the context of tumor immune evasion.
- Future directions: The study suggests further investigation into the regulation of tumor immune evasion by STAG2, which could provide deeper insights into the tumor suppression mechanisms of the cohesin complex. The clinical correlations also highlight the potential of STAG2 as a biomarker for predicting response to PD-1 blockade therapy.
Summary updated